Business - Google News
Ablynx Rises on Drug Licensing Deal With AbbVie: Brussels Mover - Bloomberg
Ablynx Rises on Drug Licensing Deal With AbbVie: Brussels Mover Bloomberg Ablynx NV, a Belgian developer of an experimental drug against rheumatoid arthritis, rose to the highest price in more than two years after selling rights to the treatment to AbbVie Inc. for as much as $840 million. Ablynx climbed as much as 14 percent to 8.47 ... Ablynx, AbbVie Sign Global License Agreement For Anti-IL-6R Nanobody, ALX ... |
No comments:
Post a Comment